Vesper Bio

Vesper Bio is a Danish biotech advancing a novel therapeutic approach for neurodegenerative diseases by targeting the multifunctional receptor sortilin. The company's lead asset, VES001, is an oral small molecule designed to normalize progranulin levels in patients with FTD-GRN and is currently in Phase II trials. Building on foundational academic research, Vesper Bio is leveraging its platform to develop selective sortilin inhibitors with potential applications in Parkinson's disease and retinal neuropathies. As a private, clinical-stage company, it operates with a sense of urgency to address significant unmet medical needs in neurology.

Oral small molecules and antibodies that selectively target the cell-surface sortilin receptor to disrupt specific pathological protein-protein interactions (e.g., with progranulin) without affecting its intracellular trafficking functions.

In FTD-GRN, competitors include gene therapy approaches (e.g., Prevail Therapeutics/ Eli Lilly's PR006) and other progranulin-elevating strategies. In the broader sortilin space, competition is less defined but could emerge from other biotechs or large pharma exploring similar biology for neurological and metabolic disorders.